Search
Close this search box.

Category

Category

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Quantexa Recognized as Category Leader in the RiskTech Quadrant® for KYC Solutions

Quantexa earned a top ranking in the RiskTech100® 2025 Report, highlighting its strength and innovation in the expanding risk technology and compliance market LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) — Quantexa, a leading provider of Decision Intelligence solutions for public and private sectors, today announced it has received recognition in

Nelson Mandela Bay Municipality cautions against spread of mpox

With the 2024 festive season looming, the Nelson Mandela Bay Municipality has urged residents to remain vigilant against the spread of mpox disease which broke out in South African earlier this year.

The metro said that on receiving the news about t…

Operation Shanela nets over 12 000 suspects

Police arrested 12 819 suspects between Monday, 14 October, and Sunday, 20 October 2024, during crime fighting activities such as tracking operations, roadblocks, high visibility patrols, stop and searches as well as the tracing of wanted suspects.

About Us

Promoting revolutionary values and uniting movements for South Africa’s economic freedom.

Newsletter

Enter your email address below to subscribe to my newsletter